These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 34669521)

  • 21. Inpatient Healthcare Resource Utilization, Costs, and Mortality in Adult Patients with Acute Graft-versus-Host Disease, Including Steroid-Refractory or High-Risk Disease, following Allogeneic Hematopoietic Cell Transplantation.
    Yu J; Judy JT; Parasuraman S; Sinha M; Weisdorf D
    Biol Blood Marrow Transplant; 2020 Mar; 26(3):600-605. PubMed ID: 31678539
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Acute graft-vs-host disease: pathobiology and management.
    Goker H; Haznedaroglu IC; Chao NJ
    Exp Hematol; 2001 Mar; 29(3):259-77. PubMed ID: 11274753
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diagnostic and prognostic role of elafin in skin acute graft versus host disease: a systematic review.
    Bhattarai A; Shah S; Yadav R; Dhakal G; Neupane R; Paudel S; Bhandari P; Abu Serhan H; Sah R; Sah S; Barboza JJ
    Hematology; 2024 Dec; 29(1):2293497. PubMed ID: 38112182
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment options in steroid-refractory acute graft-versus-host disease following hematopoietic stem cell transplantation.
    Kim SS
    Ann Pharmacother; 2007 Sep; 41(9):1436-44. PubMed ID: 17684033
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biomarkers for acute and chronic graft versus host disease: state of the art.
    Giaccone L; Faraci DG; Butera S; Lia G; Di Vito C; Gabrielli G; Cerrano M; Mariotti J; Dellacasa C; Felicetti F; Brignardello E; Mavilio D; Bruno B
    Expert Rev Hematol; 2021 Jan; 14(1):79-96. PubMed ID: 33297779
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Low-Dose Antithymocyte Globulin for Graft-versus-Host-Disease Prophylaxis in Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation.
    Bryant A; Mallick R; Huebsch L; Allan D; Atkins H; Anstee G; Sabloff M; Scrivens N; Maze D; Bredeson C; Kekre N
    Biol Blood Marrow Transplant; 2017 Dec; 23(12):2096-2101. PubMed ID: 28821454
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Graft-versus-host disease prophylaxis: Pathophysiology-based review on current approaches and future directions.
    Martinez-Cibrian N; Zeiser R; Perez-Simon JA
    Blood Rev; 2021 Jul; 48():100792. PubMed ID: 33386151
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Translational Clinical Strategies for the Prevention of Gastrointestinal Tract Graft
    Rayasam A; Drobyski WR
    Front Immunol; 2021; 12():779076. PubMed ID: 34899738
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Calcineurin Inhibitor Free Graft Versus Host Disease Prophylaxis for Patients Undergoing Matched Related and Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplant.
    Iqbal M; Nieto FAM; Brannick KM; Li Z; Murthy H; Foran J; Roy V; Kharfan-Dabaja MA; Ayala E
    Transplant Cell Ther; 2023 May; 29(5):327.e1-327.e9. PubMed ID: 36758832
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Severity of acute gastrointestinal graft-vs-host disease is associated with incidence of bloodstream infection after adult allogeneic hematopoietic stem cell transplantation.
    Modi A; Rybicki L; Majhail NS; Mossad SB
    Transpl Infect Dis; 2020 Feb; 22(1):e13217. PubMed ID: 31769584
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Etanercept for steroid-refractory acute graft versus host disease following allogeneic hematopoietic stem cell transplantation.
    Park JH; Lee HJ; Kim SR; Song GW; Lee SK; Park SY; Kim KC; Hwang SH; Park JS
    Korean J Intern Med; 2014 Sep; 29(5):630-6. PubMed ID: 25228839
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Disease progression, hospital readmissions, and clinical outcomes for patients with steroid-refractory acute graft-versus-host disease: A multicenter, retrospective study.
    Holtan SG; Yu J; Paranagama D; Tang J; Choe HK; Naim A; Joachim Deeg H; Galvin J
    Bone Marrow Transplant; 2022 Sep; 57(9):1399-1404. PubMed ID: 35739326
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Daratumumab Prevents Experimental Xenogeneic Graft-Versus-Host Disease by Skewing Proportions of T Cell Functional Subsets and Inhibiting T Cell Activation and Migration.
    Gao Y; Shan W; Gu T; Zhang J; Wu Y; Li X; Zeng X; Zhou H; Chen Z; Xiao H
    Front Immunol; 2021; 12():785774. PubMed ID: 34987512
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Blockade of TIM-1 on the donor graft ameliorates graft-versus-host disease following hematopoietic cell transplantation.
    Iliopoulou BP; Hsu K; Pérez-Cruz M; Tang SW; Pang WW; Erkers T; Kambham N; Freeman GJ; Dekruyff RH; Meyer EH
    Blood Adv; 2019 Nov; 3(21):3419-3431. PubMed ID: 31714958
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A prognostic score for acute graft-versus-host disease based on biomarkers: a multicentre study.
    Levine JE; Braun TM; Harris AC; Holler E; Taylor A; Miller H; Magenau J; Weisdorf DJ; Ho VT; Bolaños-Meade J; Alousi AM; Ferrara JL;
    Lancet Haematol; 2015 Jan; 2(1):e21-9. PubMed ID: 26687425
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recent Metabolic Advances for Preventing and Treating Acute and Chronic Graft Versus Host Disease.
    Mohamed FA; Thangavelu G; Rhee SY; Sage PT; O'Connor RS; Rathmell JC; Blazar BR
    Front Immunol; 2021; 12():757836. PubMed ID: 34712243
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Recent advances in pathophysiology, diagnosis and treatment of steroid-refractory graft-versus-host disease].
    Toubai T; Torii Y
    Rinsho Ketsueki; 2021; 62(11):1557-1566. PubMed ID: 34866077
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Longitudinal assessment of morbidity and acute graft-versus-host disease after allogeneic hematopoietic cell transplantation: retrospective analysis of a multicenter phase III study.
    Carnevale-Schianca F; Leisenring W; Martin PJ; Furlong T; Schoch G; Anasetti C; Appelbaum FR; Carpenter PA; Deeg HJ; Kiem HP; Storb R; McDonald GB; Nash RA
    Biol Blood Marrow Transplant; 2009 Jun; 15(6):749-56. PubMed ID: 19450760
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Outcomes Following Intolerance to Tacrolimus/Sirolimus Graft-versus-Host Disease Prophylaxis for Allogeneic Hematopoietic Cell Transplantation.
    Mirza AS; Tandon A; Jenneman D; Cao S; Brimer T; Kumar A; Kidd M; Khimani F; Faramand R; Mishra A; Liu H; Nishihori T; Perez L; Lazaryan A; Bejanyan N; Nieder M; Anasetti C; Pidala J; Elmariah H
    Transplant Cell Ther; 2022 Apr; 28(4):185.e1-185.e7. PubMed ID: 35017119
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety of autologous freshly expanded mesenchymal stromal cells for the treatment of graft-versus-host disease.
    Stenger E; Giver CR; Langston A; Kota D; Das PK; Chinnadurai R; Galipeau J; Waller EK; Qayed M
    Front Immunol; 2022; 13():959658. PubMed ID: 36189324
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.